Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

1003 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

1003 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

● Recruiting Phase III Respiratory / COPD / Asthma
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn’s Disease (CD)
The study is an extension of two parent studies (MLN0002-3024 [NCT04779307] and MLN0002-3025 [NCT04779320]). Participants must have participated in one of the previous studies.…
16 Apr 2026 NCT05442567
● Recruiting Phase III Oncology
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
16 Apr 2026 NCT02468024
● Recruiting Phase III Oncology
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the…
16 Apr 2026 NCT06152575
● Recruiting Phase III Cardiology / Cardiovascular
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
The purpose of the study CTQJ230A12304, is to evaluate the efficacy, safety, and tolerability of pelacarsen (TQJ230) compared to placebo in participants with ASCVD…
16 Apr 2026 NCT06813911
● Recruiting Phase III Oncology
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if…
16 Apr 2026 NCT06824467
● Recruiting Phase III Oncology
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
The purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin…
16 Apr 2026 NCT06467357
● Recruiting Phase III Oncology
A Study of BGB-16673 Compared to Investigator’s Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab [for CLL only]…
16 Apr 2026 NCT06846671
● Recruiting Phase III Oncology
Study to Evaluate INCB123667 Versus Investigator’s Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.
16 Apr 2026 NCT07214779
● Recruiting Phase III Oncology
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have…
16 Apr 2026 NCT07085767
active not recruiting Phase III Oncology
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Ongoing access to darolutamide for prostate cancer patients who benefited from previous trials, with continued monitoring.
15 Apr 2026 NCT04464226
● Recruiting Phase III Neurology
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
DEEP SEA Study Summary LP352 tested against placebo to reduce seizures in children and adults with Dravet syndrome over 24 months.
15 Apr 2026 NCT06660394
● Recruiting Phase III Oncology
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS) based on…
15 Apr 2026 NCT06117774
● Recruiting Phase III Oncology
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or…
15 Apr 2026 NCT06943872
● Recruiting Phase III Respiratory / COPD / Asthma
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very…
14 Apr 2026 NCT06883305
● Recruiting Phase III Cardiology / Cardiovascular
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
The purpose of this study is to demonstrate the efficacy and evaluate the safety and tolerability of mavorixafor in participants with congenital or acquired…
14 Apr 2026 NCT06056297
● Recruiting Phase III Oncology
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil,…
14 Apr 2026 NCT06662786
● Recruiting Phase III Oncology
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a…
14 Apr 2026 NCT06750094
● Recruiting Phase III Oncology
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of…
14 Apr 2026 NCT07225946
● Recruiting Phase III Oncology
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or…
14 Apr 2026 NCT06793215
● Recruiting Phase III Cardiology / Cardiovascular
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria, a…
14 Apr 2026 NCT05457283
● Recruiting Phase III
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO) therapy in participants…
14 Apr 2026 NCT05797610
● Recruiting Phase III
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of iptacopan in subjects with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative…
14 Apr 2026 NCT03955445
● Recruiting Phase III Rheumatology
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
The purpose of this study is to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative colitis, or…
14 Apr 2026 NCT06663332
● Recruiting Phase III Rheumatology
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this protocol is to evaluate the efficacy (how well it works), safety and tolerability of oral icotrokinra as therapy in adult…
14 Apr 2026 NCT07196748
● Recruiting Phase III Cardiology / Cardiovascular
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
14 Apr 2026 NCT05702034
● Recruiting Phase III Cardiology / Cardiovascular
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity…
14 Apr 2026 NCT07179380
● Recruiting Phase III Oncology
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or…
14 Apr 2026 NCT06615479
● Recruiting Phase III Oncology
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
The goal of this Phase 3 clinical trial is to study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients…
14 Apr 2026 NCT05671510
● Recruiting Phase III Oncology
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients…
14 Apr 2026 NCT06380751
active not recruiting Phase III
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
CAR-T cell therapy cilta-cel compared with standard chemotherapy in patients with relapsed multiple myeloma resistant to lenalidomide.
13 Apr 2026 NCT04181827
● Recruiting Phase III
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Trial testing whether adding bleximenib to venetoclax-azacitidine improves outcomes in newly diagnosed AML with specific genetic mutations.
13 Apr 2026 NCT06852222
active not recruiting Phase III Oncology
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
Adding niraparib to standard prostate cancer treatment (abiraterone and prednisone) delays cancer progression compared to standard treatment alone.
13 Apr 2026 NCT03748641
● Recruiting Phase II / Phase III
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
Aficamten improves symptoms and safety in children with obstructive hypertrophic cardiomyopathy, a serious heart muscle condition.
13 Apr 2026 NCT06412666
● Recruiting Phase III Oncology
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Trial testing new drug epcoritamab combined with existing treatments for untreated follicular lymphoma, measuring safety and effectiveness in 1095 patients.
13 Apr 2026 NCT06191744
● Recruiting Phase III Infectious Disease
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
Trial testing a group B streptococcus vaccine in pregnant women and babies to assess safety and immune response.
13 Apr 2026 NCT07160244
● Recruiting Phase III Oncology
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
New hormone therapy drug tested against standard treatment in early breast cancer patients who've completed two years of initial hormone therapy.
13 Apr 2026 NCT05774951
active not recruiting Phase III Oncology
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
TAR-200 compared to standard chemotherapy for bladder cancer recurrence after BCG in patients refusing surgery.
13 Apr 2026 NCT06211764
● Recruiting Phase III Respiratory / COPD / Asthma
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
What is being tested: Depemokimab, a biologic therapy administered as an add-on treatment, is being evaluated for efficacy and safety in patients with uncontrolled…
10 Apr 2026 NCT06961214
● Recruiting Phase III Cardiology / Cardiovascular
A Study of Navenibart in Participants With Hereditary Angioedema
What is being tested: Navenibart, a subcutaneous treatment for hereditary angioedema (HAE types 1 and 2), is being evaluated in a Phase 3 randomised…
10 Apr 2026 NCT06842823
● Recruiting Phase III Oncology
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
What is being tested: Safety and risk of tumor lysis syndrome (TLS) in treatment-naïve adults with CLL receiving venetoclax combined with either intravenous obinutuzumab…
10 Apr 2026 NCT06428019
● Recruiting Phase III Oncology
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
What is being tested: Rilvegostomig (a novel VEGF inhibitor) combined with fluoropyrimidine chemotherapy and trastuzumab deruxtecan (T-DXd) versus standard trastuzumab plus chemotherapy with pembrolizumab…
10 Apr 2026 NCT06764875
● Recruiting Phase III Oncology
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
What is being tested: Ficlatuzumab (a hepatocyte growth factor inhibitor) combined with cetuximab versus placebo plus cetuximab in patients with recurrent or metastatic HPV-negative…
10 Apr 2026 NCT06064877
active not recruiting Phase III
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
Trial testing selinexor combined with ruxolitinib versus ruxolitinib alone for untreated myelofibrosis patients.
09 Apr 2026 NCT04562389
active not recruiting Phase III Oncology
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
Nivolumab immunotherapy reduced melanoma recurrence risk compared to placebo in high-risk patients after surgery.
09 Apr 2026 NCT04099251
active not recruiting Phase III Oncology
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
TAILORx showed hormone therapy alone is sufficient for most women with early-stage hormone-responsive breast cancer, avoiding unnecessary chemotherapy.
09 Apr 2026 NCT00310180
● Recruiting Phase III
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Trial testing two new drugs (pozelimab and cemdisiran) to slow vision loss in advanced age-related macular degeneration.
09 Apr 2026 NCT06541704
● Recruiting Phase II / Phase III Neurology
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
BHV-7000 is being tested to see if it works safely in adults with focal epilepsy that doesn't respond to current drugs.
09 Apr 2026 NCT06309966
● Recruiting Phase III Oncology
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
New drug rilvegostomig combined with chemotherapy and trastuzumab deruxtecan tested against standard immunotherapy treatment for advanced HER2-positive stomach cancer.
09 Apr 2026 NCT06764875
● Recruiting Phase III Oncology
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Trial testing whether adding ficlatuzumab to cetuximab improves survival in advanced HPV-negative head and neck cancer.
09 Apr 2026 NCT06064877
● Recruiting Phase II / Phase III Diabetes / Metabolic
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
A trial testing clazakizumab (an anti-inflammatory drug) to reduce heart disease and death in dialysis patients with inflammation. Word count: 18 words
09 Apr 2026 NCT05485961